Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion mentions Verterporfin for scar-free healing and hair follicle regeneration. Human study expected within 2 years.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Low-Level Laser Therapy (LLLT) for hair loss is effective but requires consistent use and device replacement every 1-2 years. The treatment is costly, and results may not be permanent without continued use.

A user trying to avoid an expensive hair transplant, and the replies suggesting they wait two years on treatment before deciding if they need a transplant or not.

Hair growth caps and helmets using low-level laser therapy (LLLT) show potential for treating androgenetic alopecia, but more research is needed. Users often combine these devices with treatments like minoxidil and finasteride for better results.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

A hair transplant of 3361 grafts, 11.5 months after the procedure, that resulted in a very natural looking NW1 hairline; the person who underwent this procedure has not experienced any hair loss and is expecting to have no future hairloss either.

Low-level laser therapy hats for hair loss, with skepticism about their effectiveness and cost. Users suggest trying affordable alternatives instead of expensive options.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.